vs
AVADEL PHARMACEUTICALS PLC（AVDL）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
AVADEL PHARMACEUTICALS PLC的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.0倍（$77.5M vs $75.5M），AVADEL PHARMACEUTICALS PLC同比增速更快（54.9% vs 27.7%），AVADEL PHARMACEUTICALS PLC自由现金流更多（$22.2M vs $14.4M），过去两年AVADEL PHARMACEUTICALS PLC的营收复合增速更高（99.6% vs 31.3%）
Avadel Pharmaceuticals是爱尔兰的专科制药企业，专注于睡眠障碍治疗药物的研发，产品覆盖医院及基层医疗场景，总部位于爱尔兰都柏林，在美国密苏里州圣路易斯、法国里昂均设有业务运营点。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
AVDL vs PBYI — 直观对比
营收规模更大
AVDL
是对方的1.0倍
$75.5M
营收增速更快
AVDL
高出27.1%
27.7%
自由现金流更多
AVDL
多$7.8M
$14.4M
两年增速更快
AVDL
近两年复合增速
31.3%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $77.5M | $75.5M |
| 净利润 | $20.0K | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | 2.5% | 22.7% |
| 净利率 | 0.0% | — |
| 营收同比 | 54.9% | 27.7% |
| 净利润同比 | 100.8% | — |
| 每股收益（稀释后） | $0.00 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVDLPBYI
| Q4 25 | — | $75.5M | ||
| Q3 25 | $77.5M | $54.5M | ||
| Q2 25 | $68.1M | $52.4M | ||
| Q1 25 | $52.5M | $46.0M | ||
| Q4 24 | $50.4M | $59.1M | ||
| Q3 24 | $50.0M | $80.5M | ||
| Q2 24 | $41.5M | $47.1M | ||
| Q1 24 | $27.2M | $43.8M |
净利润AVDLPBYI
| Q4 25 | — | — | ||
| Q3 25 | $20.0K | $8.8M | ||
| Q2 25 | $9.7M | $5.9M | ||
| Q1 25 | $-4.9M | $3.0M | ||
| Q4 24 | $-5.0M | — | ||
| Q3 24 | $-2.6M | $20.3M | ||
| Q2 24 | $-13.8M | $-4.5M | ||
| Q1 24 | $-27.3M | $-4.8M |
毛利率AVDLPBYI
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | 90.7% | 76.5% | ||
| Q1 25 | 89.4% | 77.1% | ||
| Q4 24 | 90.5% | 76.4% | ||
| Q3 24 | 87.7% | 63.9% | ||
| Q2 24 | 93.3% | 77.4% | ||
| Q1 24 | 94.4% | 75.5% |
营业利润率AVDLPBYI
| Q4 25 | — | 22.7% | ||
| Q3 25 | 2.5% | 17.6% | ||
| Q2 25 | 13.0% | 12.7% | ||
| Q1 25 | -5.7% | 8.7% | ||
| Q4 24 | -6.5% | 22.6% | ||
| Q3 24 | -0.7% | 27.4% | ||
| Q2 24 | -30.7% | -4.6% | ||
| Q1 24 | -95.8% | -5.3% |
净利率AVDLPBYI
| Q4 25 | — | — | ||
| Q3 25 | 0.0% | 16.2% | ||
| Q2 25 | 14.2% | 11.2% | ||
| Q1 25 | -9.4% | 6.5% | ||
| Q4 24 | -10.0% | — | ||
| Q3 24 | -5.2% | 25.2% | ||
| Q2 24 | -33.3% | -9.6% | ||
| Q1 24 | -100.6% | -11.0% |
每股收益（稀释后）AVDLPBYI
| Q4 25 | — | $0.26 | ||
| Q3 25 | $0.00 | $0.17 | ||
| Q2 25 | $0.10 | $0.12 | ||
| Q1 25 | $-0.05 | $0.06 | ||
| Q4 24 | $-0.04 | $0.40 | ||
| Q3 24 | $-0.03 | $0.41 | ||
| Q2 24 | $-0.14 | $-0.09 | ||
| Q1 24 | $-0.30 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $91.6M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $98.2M | $130.3M |
| 总资产 | $199.4M | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资AVDLPBYI
| Q4 25 | — | $97.5M | ||
| Q3 25 | $91.6M | $94.4M | ||
| Q2 25 | $81.5M | $96.0M | ||
| Q1 25 | $66.5M | $93.2M | ||
| Q4 24 | $73.8M | $101.0M | ||
| Q3 24 | $65.8M | $96.7M | ||
| Q2 24 | $71.4M | $96.8M | ||
| Q1 24 | $88.8M | $107.2M |
总债务AVDLPBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益AVDLPBYI
| Q4 25 | — | $130.3M | ||
| Q3 25 | $98.2M | $115.3M | ||
| Q2 25 | $90.7M | $104.7M | ||
| Q1 25 | $74.1M | $97.1M | ||
| Q4 24 | $73.8M | $92.1M | ||
| Q3 24 | $74.7M | $71.1M | ||
| Q2 24 | $70.3M | $48.5M | ||
| Q1 24 | $78.4M | $51.0M |
总资产AVDLPBYI
| Q4 25 | — | $216.3M | ||
| Q3 25 | $199.4M | $202.9M | ||
| Q2 25 | $187.2M | $194.9M | ||
| Q1 25 | $167.9M | $196.2M | ||
| Q4 24 | $164.2M | $213.3M | ||
| Q3 24 | $158.3M | $220.7M | ||
| Q2 24 | $157.5M | $205.0M | ||
| Q1 24 | $167.9M | $214.1M |
负债/权益比AVDLPBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $22.2M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $22.2M | $14.4M |
| 自由现金流率自由现金流/营收 | 28.7% | 19.1% |
| 资本支出强度资本支出/营收 | 0.0% | 0.0% |
| 现金转化率经营现金流/净利润 | 1110.25× | — |
| 过去12个月自由现金流最近4个季度 | — | $41.7M |
8季度趋势，按日历期对齐
经营现金流AVDLPBYI
| Q4 25 | — | $14.4M | ||
| Q3 25 | $22.2M | $9.7M | ||
| Q2 25 | $12.7M | $14.1M | ||
| Q1 25 | $-8.2M | $3.6M | ||
| Q4 24 | $7.9M | $15.6M | ||
| Q3 24 | $-6.9M | $11.0M | ||
| Q2 24 | $-18.2M | $1.0M | ||
| Q1 24 | $-29.7M | $11.2M |
自由现金流AVDLPBYI
| Q4 25 | — | $14.4M | ||
| Q3 25 | $22.2M | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | — |
自由现金流率AVDLPBYI
| Q4 25 | — | 19.1% | ||
| Q3 25 | 28.7% | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | — |
资本支出强度AVDLPBYI
| Q4 25 | — | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
现金转化率AVDLPBYI
| Q4 25 | — | — | ||
| Q3 25 | 1110.25× | 1.10× | ||
| Q2 25 | 1.31× | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
